Viking Therapeutics, Inc. (VKTX) Form 10-Q — Oct 28, 2026
Viking Therapeutics reported a Q3 2026 net loss of $183.2 million ($1.55/share) versus $90.8 million a year ago, driven by a 126% nine-month jump in R&D spend to $432.7 million as the VK2735 Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials ramp up. The company shored up its balance sheet in September 2026 with a dual offering: $316.25 million gross from 9,035,714 shares at $35.00 and $258.8 million of 2.00% convertible senior notes due 2032 (conversion price ~$50.75), bringing cash and investments to $960 million — funded through at least December 31, 2027.
Key figures
- Revenue
- 0
- Total Debt
- 258750000
- Total Assets
- 977167000
- Cash Position
- 960000000
- Shares Outstanding
- 127522189
- Cash runway
- through at least December 31, 2027
- Q3 rnd expense
- 166804000
- Net proceeds notes
- $250.6 million
- Rnd growth yoy pct
- 126
- Net proceeds common
- $296.9 million
- Gross proceeds notes
- $258.8 million
- Atm remaining capacity
- $449.8 million
- Nine month rnd expense
- 432708000
- Convertible notes coupon
- 2.00%
- New buyback authorization
- $500.0 million
- Convertible conversion price
- $50.75
- Gross proceeds common offering
- $316.25 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.